Interleukin Genetics, Inc. declared that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) [Detail Analytic Report] presented new data from post hoc analyses on the influence of Interleukin’s IL-1 genetic patterns on response to isunakinra in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology.
Ken Kornman, Chief Scientific Officer of Interleukin Genetics stated that working with Eleven Biotherapeutics to evaluate subjects in its Phase III research for the two ophthalmic indications was an exciting opportunity to demonstrate their unique ability to utilize IL-1 genetic patterns to help assess clinical response to a novel interleukin-1 receptor inhibitor in allergic conjunctivitis and dry eye. The IL-1 genetic pattern data demonstrated that isunakinra treated subjects had a differential clinical response relative to vehicle control. These findings are consistent with earlier published results showing that IL-1 genetic patterns identified individuals who were more likely to respond to another IL-1 blocking drug, anakinra, in rheumatoid arthritis.
This week on Wall Street, EBIO was definitely stealing the show from rest of titans as stock mean recommendation from pool of analysts was 2.0, comparatively equal to last week’s mean recommendation. On a scale of 1-5 (Strong Buy- Sell) stock mean target was for 12.00 while the highest it touched was 12.00. For current month, out of the pool analysts, 8 recommended for a “Hold”, 21 gave recommendation for “Buy”, 1 analysts gave underperform ratings and 17 gave preference to Strong Buy.
Olivier Brandicourt, CEO of Sanofi stated that its firm sees a strong strategic fit with Medivation, Inc. (NASDAQ:MDVN) [Detail Analytic Report] even though its tie-up proposal was rejected by the US cancer drug maker previous week, Reuters reported. The French drug maker went public with a $9.3 billion proposal to acquire Medivation on April 28 but the target reported offer undervalued the firm and its pipeline of drugs. Pfizer has also approached Medivation to express interest in a buyout, raising the possibility of a bid rivaling Sanofi’s, citing people familiar with the matter.
Brandicourt added they have a strong strategic complementarity with this firm. He didn’t say if Sanofi would raise its offer. Serge Weinberg, chairman of Sanofi stated that they will only move ahead to a point where they create value. Of course, it is out of question to say here where that point is. Sanofi is keen to boost its presence in cancer treatments and already has joined forces last year with U.S firm Regeneron in immuno-oncology. Immuno-oncology differs from traditional treatments such as chemotherapy or radiotherapy as its uses or enhances the patient’s own immune system to be able to stop the growth of cancer cells.
Brandicourt stated much had still to be done to catch up with competitors such as Switzerland’s Roche or Novartis. They are making progress with Regeneron but coming back to Medivation, the complementarity comes from the fact they are very involved in prostate cancer, Brandicourt added.
Mast Therapeutics, Inc. (NYSEMKT:MSTX) [Detail Analytic Report] recently reported that its wholly-owned subsidiary, Aires Pharmaceuticals has entered into a contract with Duke University to provide support for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical research of the firm’s product candidate AIR001 in patients with heart failure with preserved ejection fraction.
This 100 patient research known as the Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF) research will be sponsored by Duke Clinical Research Institute as the Coordinating Center for the Heart Failure Clinical Research Network and conducted at premier clinical centers in the US that are part of the HFN. Brian M. Culley, Chief Executive Officer of Mast Therapeutics stated that they appreciate the NIH’s, NHLBI’s, and HFN’s recognition of the research of AIR001 in heart failure as an appropriate area of investigation. This research will step up efforts to define the potential efficacy of AIR001 for patients who have heart failure with preserved ejection fraction. This is an area of major unmet need.
There are above 1 million heart failure hospitalizations every year in the United States, about half are patients with HFpEF, and, currently, there are no proven effective therapeutic agents available for this large patient population. The investigator initiated Investigational New Drug Application has been submitted and DCRI anticipates that the research will begin recruiting patients in the Q3 of 2016, Culley added. They look forward to supporting DCRI and the HFN on this research.